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A B S T R A C T
Obsessive-compulsive disorder (OCD) occurs in 1–3% of the general population, and its often rather
early onset causes major disabilities in the everyday lives of patients. Although the heritability of OCD is
between 35 and 65%, many linkage, association, and genome-wide association studies have failed to
identify single genes that exhibit high effect sizes. Several neuroimaging studies have revealed structural
and functional alterations mainly in cortico-striato-thalamic loops. However, there is also marked
heterogeneity across studies. These inconsistencies in genetic and neuroimaging studies may be due to
the heterogeneous and complex phenotypes of OCD. Under the consideration that genetic variants may
also inﬂuence neuroimaging in OCD, researchers have started to combine both domains in the ﬁeld of
imaging genetics. Here, we conducted a systematic search of PubMed and Google Scholar literature for
articles that address genetic imaging in OCD and related disorders (published through March 2014). We
selected 8 publications that describe the combination of imaging genetics with OCD, and extended it
with 43 publications of comorbid psychiatric disorders. The most promising ﬁndings of this systematic
review point to the involvement of variants in genes involved in the serotonergic (5-HTTLPR, HTR2A),
dopaminergic (COMT, DAT), and glutamatergic (SLC1A1, SAPAP) systems. However, the ﬁeld of imaging
genetics must be further explored, best through investigations that combine multimodal imaging
techniques with genetic proﬁling, particularly proﬁling techniques that employ polygenetic approaches,
with much larger sample sizes than have been used up to now.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations: ACC, anterior cingulate cortex; BDNF, brain-derived neurotrophic factor; COMT, catechol-O-methyltransferase; DAT, dopamine transporter; DLGAP, discs
large (Drosophila) homolog-associated protein; GWAS, genome-wide association study; 5-HTTLPR, serotonin transporter-linked polymorphic region; MTL, medial temporal
lobe; NAA, N-acetylaspartate; OCD, obsessive-compulsive disorder; OFC, orbitofrontal cortex; SAPAP, SAP90/PSD-95-associated protein; PRISMA, systematic reviews and
meta-analysis; SLC1A1, solute carrier family 1 (neuronal/epithelial high afﬁnity glutamate transporter); SLC6A3, solute carrier family 6 (neurotransmitter transporter
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Obsessive-compulsive disorder (OCD) is a heterogeneous
psychiatric disorder characterized by clinically signiﬁcant recur-
rent, intrusive, and disturbing thoughts (obsessions) and by
repetitive behaviors that are aimed at reducing anxiety or dread
(compulsions) (American Psychiatric Association, 2000, 2013). It is
estimated that the lifetime prevalence of OCD is 1–3% in the
general population (Flament et al., 1988; Fontenelle and Hasler,
2008), suggesting that each of our social networks may contain
family members, friends, or colleagues that live with this often
debilitating condition (Ayuso-Mateos, 2006). The rather high
burden of OCD and its elusive etiology emphasize the urgent need
for additional research into the neurobiological pathways that
cause the disorder and the identiﬁcation of biomarkers for its
prediction and prevention (Fineberg et al., 2012).
A variety of imaging techniques have allowed researchers to
delve deep into the brains of OCD patients to seek out aberrations
in the neural circuits that control behavior. The most consistent
impairments have been found in cortico-striato-thalamic loops
(Brem et al., 2012; Maia et al., 2008; van den Heuvel et al., 2010;
Walitza et al., 2014a), which connect regions of the neocortex with
the striatum and the thalamus to form important feedback loops
that regulate neural activity. The cortico-striato-thalamic loops are
centrally involved in motor, cognitive, and affective processes, and
are assumed to be causally related to OCD symptom generation
(Brem et al., 2012; van den Heuvel et al., 2010). Structural magnetic
resonance imaging studies have revealed that mainly areas of the
medial prefrontal wall – which contains the anterior cingulate
cortex (ACC) and adjacent areas -, orbitofrontal cortex (OFC),
striatum, and thalamus are impaired in OCD (Huyser et al., 2009;
Menzies et al., 2008; Montigny et al., 2013; Peng et al., 2012; Radua
et al., 2010). Studies that used diffusion tensor imaging to
investigate the integrity of ﬁber connections have revealed that
these prefrontal areas (e.g., ACC and OFC) exhibit altered structural
connectivity (Peng et al., 2012; Piras et al., 2013). Similar regions
have also been identiﬁed using functional neuroimaging, mainly
during error processing, inhibition, and decision-making tasks, but
also during rest (Brem et al., 2012; Harrison et al., 2013; Huyser
et al., 2009). Despite these overlapping ﬁndings, it must be noted
that the neuroimaging ﬁndings in OCD vary widely across studies,
and it is not possible to attribute OCD to a single dysfunctional
region or network. This heterogeneity is most likely caused by a
rather broad spectrum of OCD phenotypes regarding symptom-
atology, severity, and (last but not least) by the different genetic
background. Therefore, the integration of neuroimaging and
genetic methods should not only focus on patients’ phenotypes,
but also on an endophenotypic analysis of unaffected relatives;
such integration may improve basic research ﬁndings.
Although OCD has a strong genetic background and high
familiality (Pauls, 2008; van Grootheest et al., 2005; Walitza et al.,
2010), the identiﬁcation of single causal gene variants has
remained difﬁcult. Many molecular-genetic studies of OCD have
investigated candidate genes, including those that encode proteins
involved in serotonergic [e.g. the SLC6A4/serotonin transporter-
linked polymorphic region (5-HTTLPR)], dopaminergic [e.g. cate-
chol-O-methyltransferase (COMT)], and glutamatergic systems
(e.g. SLC1A1 and DLGAP1), as well as other systems (e.g.
neurotrophic pathways, cell adhesion, and synaptic plasticity). A
recent meta-analysis of association studies conﬁrmed that several
risk genes are signiﬁcantly associated with OCD (Taylor, 2013).
Moreover, a recent ﬁrst genome-wide association study (GWAS)
discovered several new candidates (Stewart et al., 2013b).
According to the GWAS, the lowest two P-values were located
within the DLGAP1 gene, a member of the neuronal postsynaptic
density complex. However, thus far neither linkage studies norGWAS have identiﬁed any candidate genes with a large effect size.
Given that many psychiatric disorders are a complex result of a
variety of genetic and environmental factors, each genetic variant
accounts for only a small increment in risk of developing the
disorder. Therefore, multi-gene risk factors are currently hypothe-
sized to be better predictors for complex disorders (Hibar et al.,
2011; International Schizophrenia et al., 2009; Meda et al., 2012).
In the last decade, technological advances in neuroimaging and
molecular genetics have facilitated the implementation of imaging
genetics, a new strategy that enables to identify the effects of
susceptibility genes on the brain (Domschke and Dannlowski,
2010; Pine et al., 2010; Willeit and Praschak-Rieder, 2010).
Notably, genetic susceptibility effects are mediated by molecular
and cellular mechanisms, which in turn modulate behavioral
phenotypes by affecting the structural and functional properties of
neural circuits (Atmaca et al., 2011; Hesse et al., 2011; MacMaster,
2010; Wu et al., 2012). Therefore, such translational studies that
implement genetics and imaging techniques may reveal the
etiology of OCD more precisely (MacMaster, 2010). The combina-
tion of genetic variants and imaging techniques has recently been
explored as a tool for personalized medicine and the speciﬁcity of
imaging ﬁndings (Bifﬁ et al., 2010; Hibar et al., 2011; Kohannim
et al., 2012; Meda et al., 2012; Nikolova et al., 2011; Stice et al.,
2012). In this systematic review, we present an exploration, to our
knowledge for the ﬁrst time, of the current literature involving
imaging genetics in OCD. We discuss the main results and
limitations of these investigations.
2. Experimental procedures
We conducted a systematic review using the preferred
reporting items for systematic reviews and meta-analysis criteria
(PRISMA) (Liberati et al., 2009; Moher et al., 2009). Articles were
searched to include studies that described imaging genetics in OCD
(see PRISMA ﬂow diagram in Supplementary Figure S1). In order to
expand the literature search results, a second step included
psychiatric disorders known to be often comorbid to OCD (Kichuk
et al., 2013) (e.g. Tourette and tic disorder, anxiety, panic,
substance abuse, bipolar disorder, and depression) or healthy
controls. No limits on publication date or publication status were
imposed. Articles were identiﬁed in PubMed and Google Scholar.
The ﬁnal search was launched on March 6th, 2014. For more details
regarding the literature search and keywords, see Supplementary
Figure S1. The reference list from each extracted article was
reviewed to add manuscripts of potential interest. Two authors
(E.G. and S.W.) conducted these searches independently. A total of
718 articles were identiﬁed in the ﬁrst step using the keywords
cited in supplementary Figure S1. Sixty-three of these articles were
selected; they referred to ‘‘imaging-genetics’’ studies in OCD and
for the second step also the comorbid disorders or more speciﬁcally
referred to the effects of genes that were associated with OCD on
neuroimaging ﬁndings in patients with comorbid psychiatric
disorders.
3. Results
We began the search by looking for all publications that
involved ‘‘imaging genetics’’ in OCD. This stipulation led to the
retrieval of a small collection of manuscripts describing association
analyses of genetic variants with neuroimaging techniques in OCD
(n = 8). The present study focused on the most signiﬁcant and
nominally signiﬁcant genes associated with OCD as inclusion
criteria by cross-referencing these publications with GWAS and
meta-analyzed genetic association (Azzam and Mathews, 2003;
Lin, 2007; Pooley et al., 2007; Stewart et al., 2013a, 2013b; Taylor,
2013; Walitza et al., 2014b). A publication by Hoexter et al. (2009)
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association results in addition to their ﬁndings of single-photon
emission computed tomography or magnetic resonance imaging in
OCD. This particular publication describes the protocol of an
ongoing study of treatment response to either a selective serotonin
reuptake inhibitor (ﬂuoxetine) or cognitive behavioral therapy
compared with controls, in which the authors plan to combine
ﬁndings generated from genetics (variable number of tandem
repeats in the 30-UTR of the dopamine transporter/SLC6A3),
neuropsychology, structural magnetic resonance imaging, and
molecular neuroimaging of the dopamine transporter (Hoexter
et al., 2009). Table 1 summarizes all imaging-genetic ﬁndings
regarding genes associated with OCD. Of the 18 genes found to
have an association with OCD listed in the table, eight (encoding
HTTLPR, SLC1A1, GRIN2B, DLGAP1, DLGAP2, SLC6A3, MOG, and
CACNA1C) were studied in the context of ‘‘imaging genetics’’ in
OCD.
3.1. The serotonergic system
The ﬁrst group of genetic imaging ﬁndings in OCD involves the
serotonergic system. Hesse et al. (2011) reported that serotonin
transporter availability in the midbrain, measured using positron
emission tomography and the serotonin transporter-selective
radiotracer [11C]DASB, was signiﬁcantly increased in OCD patients
carrying the SS genotype of the 5-HTTLPR. In addition, compared
with patients with early-onset OCD or control subjects, late-onset
OCD patients had signiﬁcantly lower serotonin-transporter avail-
ability in the nucleus accumbens, hippocampus, occipital cortex,
nucleus caudate, putamen, thalamus, and midbrain (Hesse et al.,
2011). However, serotonergic binding results should be inter-
preted cautiously because binding effects appear to exert great
impact through 5-HTTLPR genotypes (Willeit and Praschak-Rieder,
2010). At the structural level, magnetic resonance imaging was
used to demonstrate that OCD patients carrying the S allele of 5-
HTTLPR had smaller right OFC volumes than L allele carriers
(Atmaca et al., 2011). At the genetic level, Lin et al. (2007) used a
meta-analysis to uncover a signiﬁcant association between SS
genotype and OCD (odds ratio = 1.21, 95% conﬁdence inter-
val = 1.01–1.45, p = 0.04). In contrast, a recent meta-analysis that
subdivided the 5-HTTLPR L allele into the high-functioning LA allele
and the low-functioning LG allele (Hu et al., 2006), producing a
triallelic form in which the LG allele is pooled with the S allele,
reported that being an LA allele carrier was signiﬁcantly associated
with OCD (odds ratio = 1.251, 95% conﬁdence interval = 1.048–
1.492, p = 0.001) (Taylor, 2013). Just recently, we could replicate
this ﬁnding of LA allele association with ealy onset OCD s well as
within a meta-Analysis includng early and late onset OCD (Walitza
et al., 2014b). However, up to now analysis of these gene variants
using genetic imaging techniques in related conditions under-
scored the effects of the 5-HTTLPR S allele and brain activation. In
particularly S-allele seems to play a role in the amygdala, in
anxiety-related disorders and in control participants (Domschke
and Dannlowski, 2010). Nevertheless, some conﬂicting results
have been reported in the context of another psychiatric disorder,
depression. In depression S-allele is considered as risk allele but
two independent studies produced conﬂicting results. One could
ﬁnd abnormalities in white matter in S-carriers while the other
found no effect on hippocampal volume (Alexopoulos et al., 2009;
Cole et al., 2011). Up to now, no other serotonergic candidate genes
have been investigated together with imaging techniques in OCD.
3.2. The glutamatergic system
The second group of genetic imaging ﬁndings in OCD involves
the glutamatergic system. So far, only candidate genes of theglutamatergic system have been replicated in both association and
linkage studies of OCD. Therefore, the glutamtergic system is of
special interest for imaging genetics. Arnold et al. (2009a) reported
an increased thalamic volume in OCD patients with the AA
genotype of the SLC1A1 (solute carrier family 1 (neuronal/
epithelial high afﬁnity glutamate transporter), member 1)
rs3056 variant. SLC1A1 gene encodes a high-afﬁnity excitatory
amino acid transporter which is selectively expressed in the
central nervous system. In contrast, Wu et al. (2012) uncovered a
trend between rs301430 in SLC1A1 and increased thalamic volume.
Both observations might be caused by transcriptional alterations,
because both variants lie in the 30 untranslated region of the
SLC1A1 gene (Arnold et al., 2009a; Wendland et al., 2009). In
addition to the glutamate transporter the N-methyl-D-aspartate
(NMDA) receptors, a class of ionotropic glutamate receptors, are of
special interest in OCD. Not only that NMDA receptor gene variants
were suggested to associate with OCD (Alonso et al., 2012),
dysfunction of NMDA receptors neurotransmission activity were
suggested to be involved in OCD (Richter et al., 2012) as well as to
mediate fear conditions (Davis, 2011). The NMDA receptor
channels are heteromers, composed of three different subunits:
NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D). The NR2
subunit acts as the agonist binding site for glutamate and is the
predominant excitatory neurotransmitter receptor in the mam-
malian brain. Moreover, the NMDA receptors are thought to be
involved in neurodevelopmental processes of the nervous system,
as with the GRIN2B and GRIN2A (Endele et al., 2010; Hall et al.,
2007). Although a meta-analysis by Taylor (2013) found no
association between GRIN2B and OCD, imaging-genetic ﬁndings
suggest that GRIN2B affects glutamatergic concentrations in the
ACC of OCD patients (Arnold et al., 2009b), as well as volumes in
the ACC, OFC (Arnold et al., 2009a), and thalamus (Wu et al., 2012).
Moreover, a new candidate gene for OCD risk, which encodes
DLGAP (SAPAP-related) (Bienvenu et al., 2009; Stewart et al.,
2013b; Zu¨chner et al., 2009), was recently reported to affect ACC
and OFC volume in OCD (Wu et al., 2012). The DLGAP2 gene
encoding the SAP90/PSD-95-associated protein 2 (SAPAP2) is
located at the post-synaptic density of neuronal cells and it
contributes to synaptic functioning. Such alterations might be
linked to the synaptic functionality of this protein in excitatory
synapses, particularly during glutamatergic synaptic transmission
(Bresler et al., 2001; Wan et al., 2011, 2013; Welch et al., 2004). In
contrast, the gene encoding DLGAP2 (SAPAP2) has been associated
with reduced OFC white matter volume in OCD (Wu et al., 2012);
DLGAP2 status has not yet been studied as a risk factor for OCD.
3.3. Dopaminergic and other genes
To date, Scherk et al. (2009) have published the only study to
combine genetic imaging ﬁndings in OCD and dopaminergic genes.
They investigated the inﬂuence of the VNTR polymorphism of the
dopamine transporter (DAT1/SLC6A3) gene on the metabolic ratios
NAA/choline, NAA/creatine, choline/creatine, and Ins/creatine in
various brain regions using 1H-magnetic resonance spectroscopy
in patients with OCD or bipolar disorder and healthy controls. They
found signiﬁcant increases of the metabolic ratios NAA/choline and
NAA/creatine in the left putamen of all subjects carrying the 10/10-
repeat DAT1 genotype (Scherk et al., 2009). They hypothesized that
this increased ratio of the homozygote DAT1 VNTR 10/10-repeat
might be associated with higher dopaminergic activity in the left
putamen of these individuals (Scherk et al., 2009). Nevertheless,
the effects of the DAT1 VNTR genotype on metabolic ratios were
observed in all individuals irrespective of diagnostic status (Scherk
et al., 2009). Therefore, there is currently no evidence of
dopaminergic gene variations in neuroimaging ﬁndings in OCD.
Furthermore, according to Taylors’ meta-analysis (2013) no
Table 1
The most signiﬁcant genetic variations associated with obsessive-compulsive disorder (OCD) and their interactions in imaging genetics.
No Functional
group
Genetic
polymorphism
Chromosomal
location
Association study
in OCD
Meta-analysis
in OCDa
GWAS analysis
in OCDa
PET/SPECT Magnetic
resonance
spectroscopy
Diffusion
tensor
imaging
Structural MRI/fMRI
1 Serotonergic
system
SLC6A4
(5-HTTLPR)
17q11.2 See meta-analysis (Lin, 2007;
Taylor, 2013;
Walitza et al.,
2014b)
N/Avail SERT availability increase
in midbrain of SS-
genotypes SERT-LPR in
adult OCD (n=6 EO-OCD,
n=13 LO-OCD, n=21
control)– PET [11C]DASB
(Hesse et al., 2011)
N/Avail N/Avail Reduced OFC volume
in S-allele in adult OCD
(n=40 OCD, n=40
control)- MRI-T1
(Atmaca et al., 2011)
2 HTR2A 13q15-q21 See meta-analysis (Taylor, 2013) N/Avail N/Avail N/Avail N/Avail N/Avail
3 MAOA Xp11.3 See meta-analysis (Taylor, 2013) N/Avail N/Avail N/Avail N/Avail N/Avail
4 Glutamatergic SLC1A1
(Glutamate
transporter)
9p24 See meta-analysis (Taylor, 2013) N/Avail N/Avail N/Avail N/Avail Increased thalamic
volume of AA genotype
(rs3056) in childhood
& adolescent OCD
(n=31)- MRI (Arnold
et al., 2009a)
Increased total ACC
gray matter volume
and decreased total
thalamic volume in
childhood &
adolescent OCD
(n=20)- MRI (Wu
et al., 2012)
5 GRIK2 6q16.3 See meta-analysis (Taylor, 2013) (Stewart
et al., 2013b)
N/Avail N/Avail N/Avail N/Avail
6 GRIN2B 12p12 See meta-analysis NOT signiﬁcant
(Taylor, 2013)
N/Avail N/Avail Reduced glutamatergic
concentrations in ACC of
GG genotype (rs1019385)
in childhood & adolescent
OCD (n=16) (Arnold et al.,
2009b)
N/Avail Increased left OFC and
right ACC volume of A-
carriers (rs1805476) in
childhood &
adolescent OCD
(n=31)- MRI (Arnold
et al., 2009a)
Increased total
thalamic volume in
childhood &
adolescent OCD
(n=20)- MRI (Wu
et al., 2012)
7 DLGAP1
(SAPAP-related)
18p11.31 See GWAS analysis N/Avail (Stewart
et al., 2013b)
N/Avail N/Avail N/Avail Increased total ACC
volume in childhood &
adolescent OCD
(n=20)- MRI (Wu
et al., 2012)
8 DLGAP2
(SAPAP-related)
8p23 See GWAS analysis N/Avail N/Avail N/Avail N/Avail N/Avail Reduced OFC white
matter volume in
childhood &
adolescent OCD
(n=20)- MRI (Wu
et al., 2012)
9 Dopaminergic COMT 22q11.21 See meta-analysis Only in male OCD
(Azzam and
Mathews, 2003;
Pooley et al., 2007;
Taylor, 2013)
N/Avail N/Avail N/Avail N/Avail N/Avail
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Table 1 (Continued )
No Functional
group
Genetic
polymorphism
Chromosomal
location
Association study
in OCD
Meta-analysis
in OCDa
GWAS analysis
in OCDa
PET/SPECT Magnetic
resonance
spectroscopy
Diffusion
tensor
imaging
Structural MRI/fMRI
10 SLC6A3 (DAT1) 5p15.3 See meta-analysis (Taylor, 2013) N/Avail N/Avail 10-repeat homozygotes
exhibit higher NAA/choline
and NAA/creatine in the left
putamen- Adult bipolar
disorder (n=30)+OCD (n=17)
& Control (n=16) (Scherk
et al., 2009)
N/Avail N/Avail
11 DRD3 3q13.3 See meta-analysis (Taylor, 2013) N/Avail N/Avail N/Avail N/Avail N/Avail
12 DRD2 11q23 See meta-analysis NOT signiﬁcant
(Taylor, 2013)
N/Avail N/Avail N/Avail N/Avail N/Avail
13 Others BTBD3 20p12.2 See GWAS analysis N/Avail (Stewart
et al., 2013b)
N/Avail N/Avail N/Avail N/Avail
14 FAIM2 12q13 See GWAS analysis N/Avail (Stewart
et al., 2013b)
N/Avail N/Avail N/Avail N/Avail
15 BDNF 11p13 See meta-analysis NOT signiﬁcant
(Taylor, 2013)
N/Avail N/Avail N/Avail N/Avail N/Avail
16 MOG 6p22.1 One family-based
OCD study (n=160)
(Zai et al., 2004)
N/Avail N/Avail N/Avail N/Avail N/Avail Total white matter
volumes of OCD
patients were larger
than those of healthy
controls, particularly
in patients carrying the
MOG G511C
(Val142Leu) Val/Val
genotype. Adult OCD
(n=30) and Control
(n=30).- MRI (Atmaca
et al., 2010)
17 CACNA1C 12p13.3 N/Avail N/Avail N/Avail N/Avail N/Avail N/Avail Amygdala gray matter
volumewas affected in
hemisphere and
diagnosis of SZ (n=21)
versus controls
(n=16), and was
genotype-speciﬁc for
rs1006737, while no
effect was found in
OCD (n=7) or bipolar
disorder (n=28)- MRI
(Wolf et al., 2013)
18 GPRC6A 6q22.1 See GWAS analysis N/Avail (Stewart
et al., 2013b)
N/Avail N/Avail N/Avail N/Avail
ACC, anterior cingulate cortex; BDNF, brain-derived neurotrophic factor; BTBD3, BTB (POZ) domain containing 3; COMT, catechol-O-methyltransferase; DAT, dopamine transporter; DLGAP, discs, large (Drosophila) homolog-
associated protein; DRD2, dopamine D2 receptor; DRD3, dopamine D3 receptor; EO-OCD, early-onset OCD; FA, fractional anisotropy; FAIM2, Fas apoptotic inhibitory molecule 2; fMRI, functional magnetic resonance imaging;
GNAQ, guanine nucleotide-binding protein (G protein), q polypeptide; GNG2, guanine nucleotide-binding protein (G protein), gamma 2; GPRC6A, G-protein coupled receptor family C group 6member A; GRIK2, glutamate receptor,
ionotropic, kainate 2; GRIN2B, glutamate receptor, ionotropic, N-methyl D-aspartate 2B; HTR2A, serotonin receptor 2A; 5-HTTLPR, serotonin transporter promoter polymorphism; LO-OCD, late-onset OCD; MAOA, monoamine
oxidase A; MRI, magnetic resonance imaging; N/Avail, Not available; NAA, N-acetylaspartate; OCD, obsessive-compulsive disorder; OFC, orbitofrontal cortex; PET, positron emission tomography; SAPAP, SAP90/PSD-95-associated
protein; SERT, serotonin transporter; SLC1A1, solute carrier family 1 (neuronal/epithelial high-afﬁnity glutamate transporter); SLC6A3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; SLC6A4, solute
carrier family 6 (neurotransmitter transporter, serotonin), member 4; SPECT, single-photon emission computed tomography.
a Findings of signiﬁcant or nominal association with OCD.
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Fig. 1. Schematic illustration of regions inﬂuenced by genetic variations in
obsessive-compulsive disorder. Variants of the serotonergic system have been
shown to inﬂuence the orbitofrontal cortex (green) and the raphe nuclei (not
shown). Glutamatergic gene variations also inﬂuence the orbitofrontal cortex; they
affect the anterior cingulate cortex and the thalamus (both blue). Dopaminergic
genes appear to inﬂuence the putamen (red). All of these regions are also assumed
to be impaired in patients with obsessive-compulsive disorder relative to healthy
control participants.
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DAT1 VNTR gene variant – could be conﬁrmed and only very small
effect sizes have been shown for DAT1 in OCD so far (see review
Brem et al., 2014).
Atmaca et al. (2010) recently published a study that combined
magnetic resonance imaging measurements with analysis of the
myelin oligodendrocyte glycoprotein (MOG) gene polymorphism,
which was of interest in the context of OCD because of the positive
results of a family-based association study (Zai et al., 2004). The
work of Atmaca et al. (2010) demonstrated that the total white
matter volumes of OCD patients were larger than those of healthy
controls, particularly among patients carrying the MOG G511C
(Val142Leu) Val/Val genotype. Similarly, a publication by Wolf
et al. (2013) combined the magnetic resonance imaging technique
with the examination of a polymorphism (rs1006737) in a gene
that encodes the alpha-1C subunit of the L-type voltage-gated
calcium channel (CACNA1C), which has been implicated in
structural and functional variation in the amygdala in healthy
people as well as in patients with bipolar disorder or schizophrenia
(Jogia et al., 2011; Perrier et al., 2011; Tesli et al., 2013; Wessa et al.,
2010). Nevertheless, up to now, there are no association studies
between CACNA1C and OCD; however, there is some indication of
an association with the predisposition to develop schizophrenia
(Green et al., 2010; Nyegaard et al., 2010) or bipolar disorder
(Ferreira et al., 2008; Sklar et al., 2008), as well as increased signs of
depression, anxiety, or obsessive-compulsive thoughts (Erk et al.,
2010; Roussos et al., 2011). In healthy volunteers, carriers of the
CACNA1C risk variant exhibited alterations in hippocampal and
anterior cingulate cortex activation as measured by functional
magnetic resonance imaging (Erk et al., 2010). In addition to the
above ﬁndings, a signiﬁcant higher psychopathology scores for
obsessive-compulsive thoughts in the risk allele carriers were
found, correlating negatively with the observed regional brain
activation (Erk et al., 2010). Wolf et al. (2013) investigated whether
amygdala volumes differed between hemispheres, diagnostic
groups (schizophrenia, bipolar disorder, OCD, and healthy con-
trols), or genotype groups, and examined the interaction of these
three parameters. They were able to demonstrate effects of
hemisphere and diagnosis of schizophrenia versus controls, in
which amygdala gray matter volume was affected and was
genotype-speciﬁc for CACNA1C; however, no alterations in
amygdala gray matter of OCD and association with genotypic
changes were observed in the OCD group (Wolf et al., 2013).
When we expanded our search to include general publications
discussing ‘‘imaging genetics’’ and comorbid psychiatric disorders
or healthy controls involving the 16 genes in Table 1, most of these
genes were signiﬁcantly associated both with OCD as such (in pure
genetic association studies) and with brain imaging data in non-
OCD pathologies, with the exception of four genes (encoding DRD3,
GRIK2, BTBD3, and FAIM2) that exhibited genetic associations with
OCD, but have not yet been studied in the context of imaging
genetics (Suppl. Table S1). This analysis added 43 publications to
our systemic review. The preponderance of publications investi-
gated polymorphisms in the DAT1, COMT, BDNF, and the serotonin
transporter (SERT/HTTLPR/SLC6A4), mostly in populations other
than OCD patients. The reports of imaging-genetics associations
were conﬂicting, particularly in investigations involving BDNF
polymorphism.
4. Discussion
To date, only eight imaging genetics studies that investigate the
association between OCD and genetic variation have been
published. Most of these genetic associations have been proven
by meta-analysis and/or GWAS (Table 1). By adding studies with
comorbid psychiatric disorders and healthy controls, we extendedthe publication collection to include other associated genes in the
context, which have been found to be associated with OCD (e.g.
BDNF, COMT), but which have not yet been investigated with
imaging techniques in OCD. This very small collection of studies
underscores the lack of knowledge in this research ﬁeld,
particularly regarding OCD.
Although only a small number of studies investigated OCD,
their ﬁndings provide interesting insights into the genetic
speciﬁcity of neural impairments. The OFC, ACC, striatal and
thalamic regions have often been shown to be associated with OCD
(Brem et al., 2012, 2014; Montigny et al., 2013; Peng et al., 2012;
Radua et al., 2010). Regions of these cortico-striato-thalamic loops
also seems to be sensitive to speciﬁc genetic variations (Fig. 1). The
OFC and the midbrain surrounding the raphe nuclei have been
associated with variants of the 5-HTTLPR. The raphe nuclei are well
known to incorporate serotonergic neurons that project to several
cortical regions. One of the main target regions of these projections
is the OFC (Cools et al., 2008), which is well known for decision
making and learning (Hauser et al., 2014; Hunt et al., 2012; Kable
and Glimcher, 2007), and is impaired in OCD (Cavedini et al., 2006;
Graybiel and Rauch, 2000; Sachdev and Malhi, 2005). Additional
support for a serotonergic involvement comes from pharmacolog-
ical treatment and in vivo studies: serotonergic medication is the
ﬁrst choice pharmacological treatment with high effect sizes and
serotonergic depletion induced OCD-like behaviors in monkeys
(Clarke et al., 2004, 2005, 2007) and in humans (Seymour et al.,
2012). However, it must be noted that the imaging genetics studies
did only focus on serotonin transporter gene (5-HTTLPR) variants
and up to now did not include other serotonergic gene variants
(e.g. serotonin receptors, metabolizing enzymes). Moreover,
within the 5-HTTLPR they did not yet differentiate between the
different 5-HTTLPR variants, i.e. the LG and LA carries (Hu et al.,
2006). Such a differentiation, however, has been shown to have
strong functional implications (Hesse et al., 2011; Willeit and
Praschak-Rieder, 2010) and might also affect cortical regions.
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on neuroimaging in OCD. Only one dopaminergic study incorpo-
rated OCD patients into its imaging genetics analysis (Scherk et al.,
2009). The study found that the metabolism of NAA in the left
putamen was modulated by variations of the DAT1 gene. However
this genetic variant is only weakly associated with OCD. So the
effect could be unspeciﬁc for OCD but more speciﬁc for the variant
by itself.
Glutamatergic neurons are the most prevalent excitatory
neurons across the entire cortex and play a crucial role in the
cortico-striato-thalamic loops. In OCD, several regions of the
cortico-striato-thalamic loops appear to be affected by variations
in glutamatergic genes. Similarly, as in serotonergic genes, the OFC
demonstrates sensitivity to variations in glutamatergic genes. An
investigation of whether there is an interaction between the
variations of serotonergic, dopaminergic and glutamatergic genes
or whether these genes have independent effects on the OFC would
be of great interest. Glutamatergic genes also inﬂuence the
thalamus and the ACC. Both regions are assumed to play a role
in the cortico-striato-thalamic loop dysfunction in OCD (Brem
et al., 2012; Huyser et al., 2009). The ACC appears to be very
consistently involved OCD, mainly in the context of conﬂict, error,
and feedback processing (Albrecht et al., 2008; Botvinick et al.,
2004; Bush, 2010; Hauser et al., 2014; Rushworth et al., 2004).
Taken together, the published imaging genetics studies provide
evidence that OCD patients cannot be understood and therefore
treated as a homogeneous group in neuroimaging analyses. Rather,
there seems to be signiﬁcant cerebral variability between speciﬁc
gene variations in OCD patients. Importantly, regions which are
found to be associated with genetic variants often also differ
between OCD patients and controls, which might mean that the
differences observed between patients and controls are also driven
by a speciﬁc genetic subgroup. Given that genetic variations are
not yet used for between-group matching, ordinary group
differences might be inﬂuenced by the prevalence of speciﬁc
genetic variations within each group. Therefore, inconsistencies in
genetic proﬁles might also (partially) explain inconsistencies
among neuroimaging studies that focus on OCD.
One major limitation thus far is that most studies used small
sample sizes and unequally sized genetic subgroups. Genetic
association studies (esp. GWAS) are known to require extremely
large sample sizes to detect signiﬁcant genetic contributions to
psychiatric disorders. This is mainly due to the fact that genetic
variants have only small effect sizes, and that such genome-wide
studies need rigorous statistical correction mechanisms. Due to the
high costs in neuroimaging, it is still much more common to study
smaller groups of approx. 20 subjects per group. In such small
groups, however, the effect sizes of genetic variants are highly
likely not to be detectable. Only very recently, large multi-national
initiatives started to investigate imaging genetics with large
sample sizes (e.g. ENIGMA, IMAGEN, ADNI, CHARGE, Medland
et al., 2014; Thompson et al., 2014).
An additional challenge in imaging genetics is caused by the
pre-selection of genes and brain regions. Due to the small sample
sizes, researchers are forced to pre-select candidate genes as well
as brain regions-of-interest to reduce the burden of multiple
comparison correction. Although such an approach is valid and has
been used in most of the studies reported here, it also biases the
results to certain extend. Namely, it restricts ﬁndings to the prior
hypothesis and hinders the detection of novel effects and
interactions. The pre-selection of cortico-striatal-loop networks,
for example, does not allow investigating (potentially stronger)
effects outside of these loops. Furthermore, it assumes that the
neural differences between different genotypes in OCD are within
the same networks that show differences between OCD patients
and controls.Also from a genetics point of view, candidate genes which are
known to be related to OCD do not necessarily predict neural
alterations. This has been shown in the ﬁrst meta-analysis imaging
genetic GWAS of the hippocampus (Stein et al., 2012). In a vast
sample of subjects, the authors did not ﬁnd a strong relation
between hippocampal volume and candidate genes. Rather, they
found associations between previously not predicted SNPs and
hippocampal volume (Stein et al., 2012). Such studies, however,
are only feasible in very large samples of patients and controls and
by using adequate statistical methods (Kochunov et al., 2014;
Medland et al., 2014).
Current research has focused on alterations in serotonergic and
glutamatergic systems. The imaging genetics ﬁndings in OCD
related to the 5-HTTLPR are still rather preliminary, and many
factors, such as comorbidity, ethnicity, therapy, sex, age (neuro-
developmental factors), and age of onset, should be considered in
future studies. Although the genetic studies show one of the
highest effect sizes for association of the glutamatergic system and
OCD, only few groups have reported ﬁndings related to imaging
genetics in OCD and genetic variants of glutamatergic genes
(Arnold et al., 2009a, 2009b; Wu et al., 2012). The results of these
investigations coincide with ﬁndings from meta-analyses and
GWAS; taken together, these observations support the involve-
ment of the glutamatergic system in OCD (Stewart et al., 2013a,
2013b; Taylor, 2013). The existing literature on imaging-genetic
studies with respect to OCD provides evidence of increasing
speciﬁcity of brain structure and/or activity ﬁndings exerted by
variants in genes involved in the serotonergic (5-HTTLPR, HTR2A)
and glutamatergic (SLC1A1, SAPAP) systems.
It must be noted that for the discussion and interpretation of the
main results of this systematic review, the interacting and
moderating effects of the heterogeneous phenotype should be
addressed in more detail. OCD is now described in the DSM-5 as an
obsessive-compulsive spectrum disorder separately to anxiety
disorders, in contrast to the previous DSM-IV criteria (American
Psychiatric Association, 2013). Nevertheless, there is a broad
phenotype range within OCD and its related disorders regarding
symptomatology and comorbidity, as well as regarding de novo
and high-familiality cases. The content of obsessions and
compulsions often concerns contamination, but can also be
focused on aggression, symmetry, precision, and religious or
sexual themes; mixed types and changes among these symptoms
are also common (Geller et al., 1998; Walitza et al., 2011). Leckman
et al. (2001) were the ﬁrst to use item-level factor analysis
(cleaning/washing, checking, symmetry/exactness, and hoarding/
saving) to describe a set of symptom dimensions that have been
validated by multiple other studies (Delorme et al., 2006; Kichuk
et al., 2013). Later studies showed high stability of these symptom
dimensions over time. In addition, a study of heritability estimates
showed that symptom dimensions display different strong genetic
background, shared environmental variance with each other and
with symptom severity. The authors presumed that the results
supported the utility of both OCD diagnosis and symptom
dimensions in genetic research and clinical contexts (Katerberg
et al., 2010). According to the DSM-5, the clinician must e.g. assign
a sub-classiﬁcation of the OCD depending on the patient’s degree of
insight. The patient’s level of insight is associated with severity and
highly associated with therapy response. Furthermore, now the
subtypes of OCD with and without tic disorder (present or in the
past) must be classiﬁed (American Psychiatric Association, 2013).
This is in accordance with observations that tic-related OCD is a
very common but special phenotype that includes more males
with early onset OCD and more relatives affected with OCD and/or
tic disorders. Tic-related OCD does not respond as positively to
serotonergic-based medication alone, and more often requires
augmentation strategies using atypical antipsychotic medications.
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studies were able to include only drug-naı¨ve patients. Most studies
should be assumed to include at least a few patients that were on
medications, ideally at stable dosages. It is obvious that these
different phenotypes and conditions interact with imaging and/or
genetic ﬁndings as well as with imaging genetic studies. Therefore,
the use of larger sample sizes with phenotypes that are more
homogeneous, as well as the use of endophenotypic approaches
(Manoach and Agam, 2013) that include unaffected relatives,
might help to deal with limitation factors caused by the
heterogeneous phenotypes.
Nevertheless, to date, only univariate analyses using one gene
variant and one brain region of interest at a time have been used for
imaging genetics in OCD. Recently, several studies of patients with
schizophrenia, patients with Alzheimer’s disease, and healthy
controls implemented a combination of imaging techniques and
GWAS ﬁndings to identify polygenetic risk loads that affect speciﬁc
brain structures, functions, or connectivity (Bedenbender et al.,
2011; Mattingsdal et al., 2013; Meda et al., 2012; Medland et al.,
2014; Nymberg et al., 2013; Whalley et al., 2013). These large
scale-data analyses employed various analytic techniques, such as
polygenic scoring (International Schizophrenia et al., 2009),
pathway enrichment analysis (Mattingsdal et al., 2013), multivar-
iate parallel independent component analysis (Meda et al., 2012),
clustering analysis, weight voxel co-activation network analysis,
and principal component analysis (Nymberg et al., 2013). These
techniques are still being developed, but hold great promise for the
investigation of genetic and neuronal factors underlying human
behavior, particularly psychiatric disorders. Even more promising,
the recently launched ENIGMA2 project (successor of the ENIGMA
consortium) will also include OCD and related disorders in its
mega-meta-analysis studies of GWAS and neuroimaging. This
hopefully will result in new insights in how genetic variations
inﬂuence functional and structural alterations in OCD (Thompson
et al., 2014).
In summary, only a small number of imaging studies that study
OCD also investigated imaging genetics. Such investigations have
the ability to offer insight into brain alterations, permitting
glimpses of how genetic changes may affect brain structure,
chemistry, and ultimately function. However, there is clearly a
great need for additional large multimodal imaging-genetic
studies that assess OCD, especially investigations that implement
polygenetic approaches in order to identify biomarkers for better
prediction and prognosis.
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